Education
About Us
Working with TipRanks
Follow Us
ImmunoPrecise Antibodies (IPA)
NASDAQ:IPA
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.72Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 28, 2025
|% Change Since: 4.55%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including strategic partnerships, financial strengthening, and substantial growth in AI and biologics, overshadowing concerns about increased operating expenses and broader industry challenges.Company Guidance
In the third quarter of fiscal year 2025, ImmunoPrecise Antibodies (IPA) reported strong financial and operational progress, as detailed in their earnings call. The company secured a significant strategic partnership valued between $8 million to $10 million, leveraging its proprietary B-cell select technology and AI capabilities. The relocation of IPA's headquarters to Austin, Texas, aims to enhance its presence in the U.S. biotech and AI ecosystem. Financially, IPA raised $8.8 million in equity, completed the full conversion of the Yorkville debenture, and ended the quarter with CAD12.9 million in cash, significantly reducing financial risk. The company reported a consistent revenue of $6.2 million, with BioStrand achieving a remarkable 131.8% year-over-year revenue increase and an average gross profit margin of 97% year-to-date. IPA's strategic initiatives include a potential divestiture of its EU lab to enhance operational efficiency and focus. The company anticipates that its AI-driven platforms will continue to scale, enhancing profitability and positioning IPA for sustainable long-term growth.Strategic Partnership
Secured a strategic partnership valued at US$8 million to US$10 million with a leading biotech company, leveraging proprietary B-cell select technology and AI-driven capabilities.
Relocation and Expansion
Relocated corporate headquarters to Austin, Texas, expanding US footprint in a thriving AI and biotech ecosystem.
Financial Strength
Strengthened financial position with US$8.8 million equity raise and full conversion of Yorkville debenture, making the company debt-free.
AI and Biologics Growth
BioStrand achieved a 131.8% year-over-year revenue increase with an average gross profit margin of 97% year-to-date.
Partnerships and Collaborations
Collaborations with key technology partners like Vultr and AMD, enhancing lab-in-a-loop drug discovery capabilities.
---
IPA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IPA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 28, 2025 | $0.44 | $0.39 | -11.36% |
| Dec 10, 2024 | $0.42 | $0.40 | -4.76% |
| Sep 16, 2024 | $0.67 | $0.54 | -19.40% |
| Jul 29, 2024 | $0.86 | $0.83 | -3.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ImmunoPrecise Antibodies (IPA) report earnings?
ImmunoPrecise Antibodies (IPA) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is ImmunoPrecise Antibodies (IPA) earnings time?
ImmunoPrecise Antibodies (IPA) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IPA EPS forecast?
IPA EPS forecast for the fiscal quarter 2025 (Q4) is -0.04.
---